European Pharmaceutical Review

20/06/2024

Semi-automation of manual interventions in high-speed filling lines
Research has highlighted the potential of using robotics for isolator filling line interventions, enabling gloveless executions by operators.

Research has highlighted the potential of using robotics for isolator filling line interventions, enabling gloveless executions by operators.

20/06/2024

💻 Don't miss our upcoming webinar... make sure to register today!

Join us as industry experts discuss the adoption of continuous manufacturing in the pharmaceutical industry. Hear first-hand experiences and strategies for implementing continuous manufacturing processes for various drug products and substances.

📅 Register now: https://bit.ly/3QZFOP7

20/06/2024

Following EMA recommendation of fruquintinib, investigator on the FRESCO-2 trial discusses the potential of small molecule drugs in .

Following EMA recommendation of fruquintinib, investigator on the FRESCO-2 trial discusses the potential of small molecule drugs in oncology.

19/06/2024

Fifty four percent of evaluable patients with DLBCL attained a substantial tumour reduction with the five-drug regimen, trial data shows.

Fifty four percent of evaluable patients with DLBCL attained a substantial tumour reduction with the five-drug regimen, trial data shows.

19/06/2024

📄 Don't miss out on our exclusive Pharma Horizons: Cell and gene therapy report!

Download now to learn more about:
✅ Training, recruitment and diversity challenges
✅ How automation and single-use systems are helping to drive down CGT costs and development timelines
✅ Defining a chemistry, manufacturing and controls (CMC) strategy
✅ Quality perspectives in navigating development of cell therapy programmes
✅ Environmental monitoring requirements for ATMP manufacturing facilities.

Access now >> https://bit.ly/454YVgH

This report has been sponsored by Bio-Techne, Fujifilm Irvine Scientific and Charles River Laboratories.

19/06/2024

Are you interested in...
❔ Airborne particle counting
❔ Aseptic processing
❔ Cleanrooms
❔ Environmental monitoring
❔ QA/QC

Then download our latest application note with MBV >> https://bit.ly/44mow4c

We hope you find it useful!

18/06/2024

The new approval of the anti-PD-1 combination therapy is indicated for certain patients with the most common gynaecologic cancer, MSD states.

The new approval of the anti-PD-1 combination therapy is indicated for certain patients with the most common gynaecologic cancer, MSD states.

17/06/2024

Currently, the Latina site exports 97 per cent of the medicine it produces, according to Johnson & Johnson.

Currently, the Latina site exports 97 per cent of the medicine it produces, according to Johnson & Johnson Innovative Medicine.

17/06/2024

⭐ New for you - Enhancing oral drug delivery: Exploring multiparticulate systems with Thermo Fisher Scientific ⭐

📅 14th August 15:00PM BST

👨‍🔬 Discover the intricacies of multiparticulate systems, exploring their design, benefits, and the issues they are uniquely positioned to solve, particularly for oral drug delivery.

You'll also benefit from viewing case studies illustrating applications of multiparticulate systems as well as taking part in a Q&A with our speaker.

Register now >> https://bit.ly/3xk1sXL

17/06/2024

💭 Wondering what the future of bioprocessing looks like?

Now's the time to download our in-depth focus with Actylis!

You'll learn about the potential of biologics production, as well as the evolution of bioconjugation technology.

Interested? Head this way >> https://bit.ly/3y0Iq8U

14/06/2024

The new, potentially multi-billion-dollar deal will help bring a next-generation therapy to patients with IBD, an condition.

The new, potentially multi-billion-dollar deal will help bring a next-generation therapy to patients with IBD, an autoimmune condition.

13/06/2024

Once-weekly or once-monthly dosing offers flexibility in haemophilia A with or without inhibitors, stated Novo Nordisk’s EVP for Development.

Once-weekly or once-monthly dosing offers flexibility in haemophilia A with or without inhibitors, stated Novo Nordisk’s EVP for Development.

13/06/2024

Ocugen's CSO Dr Arun Upadhyay, discusses promising modifier candidates for ophthalmic disorders.

Ocugen's CSO Dr Arun Upadhyay, discusses promising modifier gene therapy candidates for ophthalmic disorders.

13/06/2024

📄 Have you downloaded our new Pharma Horizons report? Now's the time!

Explore how the rapid expansion of the cell and gene therapy field has affected skills, recruitment and training needs; delve into manufacturing and quality requirements for CGTs, and discover how these new modalities are transforming clinical trials.

Read expert insights from cell and gene therapy professionals, including:
📕 Dr Ivan Wall, Professor of Regenerative Medicine at the University of Birmingham and Director of Resilience: the UK Medicines Manufacturing Skills Centre of Excellence
📕 Andrew Frazer and James Cody of Charles River Laboratories’ Gene Therapy CDMO
📕 Drew Hope, Ryan Guest, and Clare Blue from eXmoor Pharma
📕 Takehiro Okumura, PhD, Director of Cell Therapy Quality at Takeda
📕 Patricia Fox Anderson and Emily Merrell from ICON plc’s Centre for Cell & Gene Therapy

Download now: https://bit.ly/454YVgHz

This report is sponsored by Bio-Techne and FUJIFILM Irvine Scientific.

12/06/2024

Supercritical fluid chromatography is becoming a “dominant” technique for enantiomeric separation, especially purification, the paper stated.

Supercritical fluid chromatography is becoming a “dominant” technique for enantiomeric separation, especially purification, the paper stated.

12/06/2024

The UK industry body has invited proposals on economic investment, support for , clinical trials and R&D.

The UK industry body has invited proposals on economic investment, support for manufacturing, clinical trials and R&D.

12/06/2024

👨‍🔬👩‍🔬Introducing the speakers for our upcoming webinar with MasterControl 'Pharmaceutical continuous manufacturing: what’s next for industry?'

Moderator: Dr. Clifford V. Rossi – Professor, University of Maryland
Irina Ramos, PhD – Director, AstraZeneca
Sripathy Venkatraman – VP, Head of Global R&D Operations at Curia
Jan-Sebastiaan Uyttersprot – Head of Manufacturing and Powder Technology, UCB

These industry experts will discuss adoption of continuous manufacturing in the pharmaceutical industry. Don't miss this chance to engage, ask questions, and stay ahead in the industry!

Register now: https://bit.ly/3QZFOP7

12/06/2024

Tune in to the latest EPR Podcast: FAIR Data in Pharma with Giovanni Nisato, Project Manager at the Pistoia Alliance.

🎧 Listen now >> https://bit.ly/3QZDTKf

In this podcast, Giovanni Nisato, discusses data integrity and the FAIR data principles. In this role, he coordinates FAIR Community of Experts, which created the FAIR Maturity Matrix.

Giovanni starts the conversation by defining data integrity and explaining why it is ‘mission critical’ for the pharmaceutical industry.

Next, the podcast introduces FAIR (Findable, Accessible, Interoperable, Reusable) data principles and explores how their adoption have evolved over the past decade.

“This year we celebrated the 10-year anniversary of the first workshop where those FAIR data principles were reformulated. And they were then published in 2016,” Giovanni says.

Since then, the pharmaceutical industry has seen a “move towards data centricity as a way of thinking.” But adoption of the FAIR data principles is not mainstream yet.

🎧 Listen now >> https://bit.ly/3QZDTKf

12/06/2024

Developing the EU’s first intestinal microbiota-based biologic
In this final installment of EPR's Microbiome therapeutics: microscope to Medicine, Dr Olaia Aurtenetxe, Head of Clinical Research at Mikrobiomik, reveals study data demonstrating why MBK-01, an investigational drug based on faecal microbiota transplantation, presents a promising alternative to the current standard of care for Clostridioides difficile infections (CDI), potentially reducing antibiotic use and antimicrobial resistance.

This article explores the potential of a promising faecal microbiota transplantation-based therapy for Clostridioides difficile infections.

11/06/2024

To enhance , EFPIA strives “to go beyond compliance on the targets set within the various EU legislative requirements”.

To enhance Pharma sustainability, EFPIA strives “to go beyond compliance on the targets set within the various EU legislative requirements”.

11/06/2024

Webinar: Overcoming contamination risks during biologicals production: Mycoplasma & virus testing
Listen to the discussion on contamination risks in biomanufacturing, featuring mycoplasma and virus testing per European Pharmacopoeia and USP standard
Register now!

Listen to the discussion on contamination risks in biomanufacturing, featuring mycoplasma and virus testing per European Pharmacopoeia and USP standard

11/06/2024

The microparticle-based drug formulation offers a new delivery approach which could improve patient compliance, the paper stated.

The microparticle-based drug formulation offers a new delivery approach which could improve patient compliance, the paper stated.

11/06/2024

📩 Delivering straight to your page, our complete Guide to Testing 2024.

Inside, articles explore limit of detection requirements for microbial testing of short-shelf-life products and sustainable endotoxin testing.

It also includes contributions from Edwin van den Heuvel and Pieta IJzerman-Boon.

Download today: https://bit.ly/3URgfC3

11/06/2024

🚨 Join us at The Future of Bio/Pharmaceutical Analysis Online Summit! 🚨

🔍 Panel Discussion: Nitrosamine Contamination - Is it still an issue today?

Years after NDMA contamination first surfaced, we've seen improvements, but Nitrosamine Drug Substance-Related Impurities (NDSRIs) continue to be a pressing concern with new cases reported weekly. Dive into the latest on nitrosamine risk evaluation, advanced detection techniques, and the path toward international regulatory harmonization.

🎙️ Meet our experts:

- Varun Ahuja, Head of Toxicology, Syngene International
- Ivana Gusić, Senior Manager, TEVA Pharmaceuticals
- Ingrid Hegbom Ekman, Director of R&D, Cambrex
- Malcolm Ross, Analytical Specialist, Novartis
- Archana Bahuguna, Regulatory Compliance SME

🔗 Register now to gain essential insights into the evolving world of nitrosamine testing! https://bit.ly/3wiPLAf

10/06/2024

SMA patients in the long-term extension Evrysdi study maintained or improved key developmental skills over the five-year period, data shows.

SMA patients in the long-term extension Evrysdi study maintained or improved key developmental skills over the five-year period, data shows.

10/06/2024

Following advancements at a similar European facility, the new US manufacturing facility is set to produce lead-212 radioligand therapies.

Following advancements at a similar European facility, the new US manufacturing facility is set to produce lead-212 radioligand therapies.

10/06/2024

Case study: Data-driven water system maintenance
This case study looks at how an online microbial analyzer provides real-time bioburden monitoring for rapid response to adverse water system events.
Discover more below

This case study looks at how an online microbial analyzer provides real-time bioburden monitoring for rapid response to adverse water system events.

10/06/2024

📚 Read now: Application of NGS to enhance the molecular monitoring of CML patients

In this Q&A with Dr Jin Li and Dr Chad Galderisi of ICON Specialty Laboratory Solutions, they discuss how Next Generation Sequencing can support more accurate monitoring of chronic myeloid leukaemia patients.

Interested? Download now: https://bit.ly/4aPg8Mi

10/06/2024

Find out how is evolving to increase focus on through development of long-acting, oral-delivery technologies.

Find out how drug delivery is evolving to increase focus on sustainability through development of long-acting, oral-delivery technologies.

07/06/2024

Is the pharmaceutical industry ready for digital innovations like AI, and are these advances are a threat or ally to IP rights.

Is the pharmaceutical industry ready for digital innovations like AI, and are these advances are a threat or ally to IP rights.